Substance Use Screening Tools: AUDIT-C, DAST-10, and ASSIST

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Substance use screening is a structured way to identify possible alcohol- or drug-related risk early enough for a meaningful clinical conversation. The AUDIT-C, DAST-10, and World Health Organization ASSIST are established questionnaires, but each answers a different question. AUDIT-C measures patterns of alcohol consumption, DAST-10 summarizes reported problems associated with nonalcohol drug use, and ASSIST examines involvement and risk separately across several psychoactive substance classes. A score helps determine what to ask next; it does not establish a psychiatric diagnosis. WHO ASSIST manual; U.S. Preventive Services Task Force drug screening recommendation.

The central clinical principle is screening followed by an appropriate response. A positive screen can prompt a confidential discussion, confirmation of substance-specific exposure, assessment of immediate safety, diagnostic evaluation when indicated, and an offer of evidence-based support. A negative screen cannot exclude every episode of exposure, overdose risk, or substance use disorder. Instrument selection depends on what substances must be covered, the population, the setting, the clinical purpose, and the care available after the questionnaire.

What Substance Use Screening Measures

Screening, assessment, and diagnosis are different clinical steps

Screening estimates the possibility of a relevant problem using a brief, standardized set of questions. Clinical assessment expands the account: what was used, when and how, quantities, route of administration, co-use, consequences, prior attempts to reduce use, medical and psychiatric conditions, medications, pregnancy when relevant, and the person's priorities. Diagnosis applies an established classification framework such as DSM-5-TR or ICD-11 to evidence obtained during an assessment. A questionnaire threshold is a signal to examine the clinical picture, not a substitute for diagnostic criteria. USPSTF guidance.

Substance use describes exposure or consumption. Risky or hazardous use refers to patterns associated with increased probability of harm. The colloquial expression substance misuse can describe nonmedical use or harmful patterns, but is less precise than specifying the observed behavior. Substance use disorder requires a recognized constellation of impaired control, functional consequences, or other diagnostic features over an applicable interval. Someone may engage in risky drinking without meeting criteria for alcohol use disorder; someone with a disorder may minimize recent consumption on a short questionnaire.

Addiction, tolerance, dependence, and withdrawal

Addiction is a clinical and research term often associated with persistent, compulsive substance seeking or use despite adverse consequences. Physiological dependence describes adaptive bodily changes that can produce a withdrawal syndrome after reduction or cessation. Tolerance indicates a diminished effect of a given amount or a need for more to achieve a similar effect. Prescribed medications can produce physiological dependence without compulsive use. Neither a withdrawal symptom nor a screening score alone demonstrates addiction. Equally, substantial substance-related risk may exist before a person reports dependence.

Why identifying risk early can matter

Screening can normalize confidential conversations about alcohol, medications, and other substances; detect patterns a routine visit might miss; and help connect a person with brief counseling, clinical assessment, medication treatment, or harm-reduction services. The evidence supporting a screen's ability to classify risk must be distinguished from evidence that the complete screening-and-response program improves health outcomes. For adult alcohol use, the USPSTF found benefit from brief behavioral counseling after detection of unhealthy use. For unhealthy drug use, the underlying systematic review found accurate instruments but no direct trials demonstrating that screening itself improved mortality or morbidity. USPSTF alcohol guidance; Patnode and colleagues' systematic review.

AUDIT-C: A Brief Alcohol Consumption Screen

What the AUDIT-C asks and who it is for

The Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) consists of the three consumption questions from the longer ten-item AUDIT. It asks about drinking frequency, typical quantity, and the frequency of heavy drinking occasions over the relevant assessment period. It is commonly used in adult primary care, medical services, and health systems that repeatedly assess alcohol-related risk. Because it focuses on exposure patterns, it can flag unhealthy consumption before social or medical consequences become apparent. Its brevity supports routine use and repeated discussions.

AUDIT-C is an alcohol instrument. It cannot screen comprehensively for cannabis, opioids, stimulants, sedatives, or other nonalcohol substances. It also cannot distinguish alcohol-related risk from a diagnosed alcohol use disorder solely on the basis of its total score. A person may meet an elevated consumption threshold without having the impairment pattern required for a disorder, while someone with an alcohol use disorder may report little recent drinking during abstinence or remission.

AUDIT-C scores and commonly used thresholds

The AUDIT-C total ranges from 0 to 12, with each question contributing 0 to 4 points. Higher totals generally indicate higher reported exposure or risk. In frequently used U.S. adult protocols, scores of 3 or more for women and 4 or more for men trigger additional assessment. These thresholds are screening conventions rather than universal biological boundaries or diagnostic rules. Different health systems may use a common cutoff, a different threshold, or special procedures for pregnancy, older age, or clinical populations. The exact algorithm and the standard-drink definitions must match the locally validated implementation. USPSTF systematic review; comparison of screening methods.

Lowering a cutoff generally increases the number of people identified for follow-up and may also increase false-positive results. Raising it can reduce unnecessary follow-up while missing some people with clinically relevant risk. In the 2018 evidence review, AUDIT-C sensitivity for unhealthy alcohol use was often high at commonly studied sex-specific cutoffs, but specificity varied widely between populations and studies. Findings should be evaluated for the particular clinical setting rather than transferred as fixed performance figures. USPSTF alcohol recommendation.

What a positive or low AUDIT-C score means

A positive result means the clinician should clarify the amount, strength, and timing of drinks; patterns of heavy episodic use; health risks; medication interactions; pregnancy-related concerns; and the patient's goals. A clinician may use a complete AUDIT, structured consumption history, and diagnostic interview if indicated. An unexpectedly low score should be interpreted alongside clinical information: recent abstinence, underreporting, a recall period that misses past problems, or an acute alcohol-related event may require additional inquiry.

Limits of interpreting alcohol consumption as a diagnosis

Alcohol consumption is measured in standard drinks only after accounting for local definitions and beverage strength. A drink containing substantially more alcohol than the standard reference changes the clinical interpretation of quantity. Self-reported frequency does not identify serum alcohol concentration, withdrawal severity, liver disease, or individual impairment. A short alcohol screen should never be used to decide whether a person with possible alcohol withdrawal can safely stop drinking without medical assessment.

DAST-10: Problems Related to Drug Use

The purpose and scope of DAST-10

The Drug Abuse Screening Test, ten-item version (DAST-10), is a condensed version of Harvey A. Skinner's original DAST. It uses ten yes-or-no items to identify consequences and experiences associated with nonmedical or nonprescribed drug use during the relevant period, typically the past 12 months. It is intended for a broad range of nonalcohol drug-related problems, including nonmedical use of prescription medications and illicit drugs as described in the instrument's instructions. Alcohol and tobacco are excluded. NIDA Common Data Elements entry; Skinner's foundational publication.

Unlike ASSIST, DAST-10 is not designed to generate a separate risk score for each substance category. Its result may reflect experiences involving one drug or multiple drugs. A high score suggests a burden of reported drug-related problems, but does not reveal which substance poses the greatest immediate risk, how recently it was taken, or whether the person meets diagnostic criteria for an opioid, stimulant, cannabis, or sedative use disorder.

DAST-10 scoring and interpretation

DAST-10 totals range from 0 to 10. Items are scored in the direction of drug-related problems, with one reverse-scored item in the standard instrument. A commonly reported descriptive scheme is 0, no problems reported; 1–2, low-level problems; 3–5, moderate problems; 6–8, substantial problems; and 9–10, severe problems. These labels refer to an instrument score, not to formal DSM-5-TR mild, moderate, or severe diagnostic categories. They also do not independently determine the required treatment intensity or clinical placement. DAST-10 validation study.

Settings may regard any nonzero score as deserving a conversation, while higher scores usually justify more extensive assessment. In one pragmatic approach, patients answering positively to a single drug use screening question receive DAST-10 to characterize problem burden. The clinical pathway should be grounded in symptoms, specific drugs, safety, patient preference, and accessible services rather than a rigid threshold-to-referral formula. Comparison of methods in primary care.

A low DAST-10 score can coexist with serious risk

A person who has recently begun using a high-potency opioid or who mixes sedatives with alcohol may report few prior consequences while facing major overdose danger. Because the DAST-10 emphasizes past-year problems and is not substance-specific, it may miss acute changes, recently emerging hazardous patterns, or specific exposure histories. A zero score can also reflect misunderstanding the definition of nonmedical drug use, reluctance to disclose, a limited recall window, or absence of established harms. Immediate safety is assessed independently of the total.

Instrument fidelity and responsible reproduction

DAST-10 uses standardized wording and scoring, including its reverse-coded response. Altering questions, adding answer choices, or silently replacing terms can change the measurement and compromise comparability with validation research. Institutions should use authorized versions and check permissions and translation validation. The National Institutes of Health instrument record identifies Harvey Skinner and the Centre for Addiction and Mental Health in relation to the instrument's copyright and noncommercial reproduction conditions. NIH instrument record.

WHO ASSIST: Substance-Specific Risk Across Multiple Classes

Purpose, scope, and structure

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was developed through the World Health Organization's international research program for use in primary and general health care. Its core standardized eight-question structure addresses lifetime and recent involvement with tobacco, alcohol, cannabis, cocaine, amphetamine-type stimulants, inhalants, sedatives or sleeping pills, hallucinogens, opioids, and other drugs. The instrument asks about use and selected problems such as urges, health and social consequences, responsibilities, others' concern, attempts to control use, and injection-related risk. WHO ASSIST manual.

A central advantage of ASSIST is that it can capture several separate substance-specific risk profiles in one assessment. Someone may have low alcohol risk and substantial opioid risk, while another may have elevated cannabis and stimulant risk. The clinician can respond to each profile rather than producing one combined label of 'addiction severity.' The instrument has more administration and scoring demands than a short prescreen, so feasibility, training, and continuity of care matter.

ASSIST scores: low, moderate, and high risk

For the standard ASSIST version 3.0 scoring scheme, alcohol scores of 0–10 indicate the instrument's low-risk range, 11–26 the moderate-risk range, and 27 or more the high-risk range. For substances other than alcohol, the corresponding ranges are 0–3, 4–26, and 27 or more. The distinction is specific to the WHO scoring system: a score of 8 has a different interpretation for alcohol than for cocaine or opioids. Risk strata guide further discussion, brief intervention, or referral consideration; they are not direct diagnostic categories. WHO manual and scoring guidance.

ASSIST scoring requires the official instructions for which questions contribute to each substance-specific score. The lifetime-use and injection-history questions do not simply add to a single universal total. Copying the numeric ranges into a different questionnaire, summing every response indiscriminately, or treating the score of one substance as a global diagnosis produces invalid results. Injection history and current injecting practices require specific safety assessment even when the numerical score is low.

How a risk profile informs follow-up

A low ASSIST score generally supports prevention-oriented feedback in the context of the patient's circumstances. A moderate score calls for more detailed discussion of health consequences, goals, and a clinically appropriate brief intervention. A high score increases concern for substantial substance-related problems and supports a comprehensive assessment, potentially involving specialist services. Actual care depends on disorder criteria, acute medical conditions, available medications, social context, and patient preference. WHO's linked brief-intervention manual is designed to follow rather than replace clinical judgment. WHO brief intervention manual.

ASSIST and polysubstance exposure

ASSIST's multi-substance perspective is especially useful when exposure to different drugs overlaps. Asking about alcohol, benzodiazepines, opioids, stimulants, and other agents may disclose interactions that a drug-only or alcohol-only instrument would miss. It remains necessary to ask directly about combinations, specific prescribed medications, potency, route, recent doses when clinically relevant, and safety symptoms. No ASSIST risk band assures protection against overdose, toxic interactions, or severe withdrawal.

AUDIT-C vs DAST-10 vs ASSIST: Which Tool Should Be Used?

Primary clinical question and measurement target

AUDIT-C is often the most efficient choice for identifying unhealthy patterns of alcohol consumption in a general adult health visit. DAST-10 offers a short summary of problems involving nonalcohol drugs, especially after a positive initial drug-use question. ASSIST suits a more comprehensive conversation in which tobacco, alcohol, prescription-drug misuse, and multiple classes of substances should be evaluated separately. These are overlapping but distinct measurement purposes. One should not automatically replace the others, and choice should reflect the health system's validated workflow.

Time, burden, and workflow

Three alcohol consumption questions are easier to integrate into a brief encounter than a multi-substance structured interview. DAST-10 may be completed quickly in self-report or interview format, but requires clarity about what counts as drug use. ASSIST can provide wider information but takes more clinician or patient time and may require scoring support or staff training. Asking a short validated prescreen followed by a more detailed instrument when indicated can balance reach with depth. USPSTF drug screening recommendation.

Information each instrument leaves out

AUDIT-C leaves out nonalcohol substances and most consequences of drinking. DAST-10 excludes alcohol and tobacco, and aggregates consequences across drugs. ASSIST yields substance-specific risk scores but still does not itself establish a complete diagnosis, acute toxidrome, treatment placement, or likelihood of recovery. None measures blood concentration, guarantees accurate recall, or replaces a supportive clinical interview. None should be used as the sole gatekeeper to urgently needed care.

Evidence for Accuracy, Reliability, and Clinical Benefit

What sensitivity and specificity tell us

Sensitivity is the proportion of people with the defined target condition who screen positive; specificity is the proportion without that target condition who screen negative. Neither is a universal property of a questionnaire independent of context. Performance changes with the reference standard, the cutoff, substance mix, language, patient population, clinical setting, and the definition of 'unhealthy use.' A study detecting any past-year cannabis use and a study detecting diagnosed opioid use disorder are measuring different clinical targets.

Positive predictive value also depends on prevalence. In a setting where the target condition is uncommon, a positive screen can be more likely to require clarification even when a tool has good sensitivity and specificity. This is why clinicians should avoid telling patients that a score proves they have an addiction. The 2020 USPSTF evidence report found reasonably accurate adult drug screening tools but also documented substantial heterogeneity and limited studies per instrument. Patnode et al., JAMA 2020.

Evidence for alcohol screening

The 2018 systematic review conducted for the USPSTF identified AUDIT-C and other one- to three-item screens as reasonably accurate for unhealthy alcohol use in adults. The evidence showed variation in specificity and gaps in pregnancy and other subgroups. Brief counseling among adults who screen positive had evidence of reducing unhealthy drinking measures, although those findings do not establish that the questionnaire itself is an active treatment. Reviews that target alcohol use disorder rather than unhealthy drinking may reach different conclusions because diagnostic classification is a harder and different task. O'Connor et al., JAMA 2018; AUDIT meta-analysis.

Evidence for drug screening

The USPSTF-commissioned 2020 systematic review included 28 screening accuracy studies involving more than 65,000 participants, but 30 instruments were assessed and most individual measures appeared in few studies. Among adults, reported sensitivity for unhealthy use of any drug across selected validated tools ranged from 0.71 to 0.94 and specificity from 0.87 to 0.97. Those pooled ranges should not be assigned automatically to DAST-10 or ASSIST in every population. Evidence was weaker for detecting misuse of prescription opioids and sedatives in some studies. Patnode et al., JAMA 2020.

The systematic review found no eligible direct studies demonstrating that routine drug screening itself reduced mortality, morbidity, or other major outcomes, although treatment evidence and plausible pathways support pairing detection with accessible care. The USPSTF consequently recommends asking adults about unhealthy drug use when accurate diagnosis, effective treatment, and suitable care can be offered or arranged. This conditional care requirement is critical to the clinical meaning of screening. USPSTF guidance.

Validation in populations and languages

A validated translation must preserve item meaning, reference periods, response choices, and scoring structure. Studies in one health system or population cannot establish identical performance in a different country, adolescent group, pregnancy setting, or cultural context. Specific concerns include variability in standard drink size, attitudes toward self-disclosure, literacy, interpretation of nonmedical prescription use, and norms surrounding drug-related stigma. Local calibration and independent evaluation may be needed before assigning an unfamiliar cutoff to patients.

From a Screening Result to a Clinical Decision

A practical sequence for responsible follow-up

A defensible workflow begins with explaining the reason for screening, obtaining answers in a private and respectful setting, and scoring the standard instrument accurately. A clinician then reviews any positive answer and urgent risk markers, clarifies the substance and temporal pattern, and determines whether a full diagnostic assessment or brief intervention is appropriate. The next steps may include counseling, medical evaluation, medication treatment when indicated, harm reduction, specialist referral, or routine preventive support. The person should understand the result and participate in decisions.

Substance use screening becomes clinically meaningful when the service can actually respond. A practice should decide in advance who interprets results, how urgent findings are escalated, which referral pathways are reliable, how follow-up is arranged, and how privacy is protected. Repeated screening without a pathway for assessment and care can document concern without helping the person address it. USPSTF primary care implementation guidance.

Positive screen with no reported impairment

A positive AUDIT-C may reflect a consumption pattern that increases risk even when the person reports no loss of control or social impairment. A low DAST-10 score might follow an admission of occasional drug use without recognized consequences. Appropriate follow-up explores context and future risk, provides nonjudgmental feedback, and determines whether a brief intervention or further assessment is worthwhile. Diagnostic labeling should depend on diagnostic evidence, not screening positivity.

Negative screen despite clinical concern

A negative answer should be reconsidered if a patient presents with an overdose, unexplained intoxication, recurring withdrawal symptoms, medication interactions, drug-related injury, or symptoms requiring urgent attention. Patients may not recognize a substance as relevant, may fear disclosure, or may be questioned while unable to provide a reliable history. A single low score is never a substitute for direct clinical evaluation when circumstances indicate high risk.

Shared decisions and language

The clinician can explain that a screening tool identifies possible areas of concern and that a higher score provides a reason to talk further. Phrases such as 'your answers suggest a pattern worth examining' are usually more accurate than categorical statements based on scores. Patients should be able to describe the role substance use plays in their lives, their reasons for change, and concerns about treatment, confidentiality, family relationships, or employment. Clear terminology helps prevent stigmatizing interpretations of a clinical questionnaire.

Safety: Problems a Routine Screening Tool Cannot Triage

Alcohol and sedative withdrawal

Alcohol withdrawal and withdrawal from benzodiazepines or related sedatives can produce seizures, delirium, and other life-threatening complications in physiologically dependent patients. A person with recent heavy long-term exposure, previous severe withdrawal, seizures, confusion, or marked autonomic symptoms needs prompt medical assessment. Screening scores should not be used to prescribe an unsupervised withdrawal plan. Where dependence is possible, abrupt cessation or rapid dose reduction may be dangerous; care decisions depend on clinical history and medical supervision.

Opioid overdose and respiratory depression

An unresponsive person with slow, absent, or abnormal breathing may be experiencing opioid overdose, especially with possible fentanyl or other opioid exposure or co-use of alcohol and sedatives. Activate emergency medical services immediately, administer naloxone if available, and follow dispatcher instructions for rescue breathing or CPR while awaiting help. Naloxone can reverse opioid-related respiratory depression and may require repeated administration or ongoing observation; a questionnaire does not determine its indication in an emergency. CDC naloxone information.

Stimulant toxicity, psychosis, and self-harm

Chest pain, collapse, severe agitation, hyperthermia, seizures, major confusion, or acute psychotic symptoms following stimulant exposure require urgent evaluation. Immediate assessment is also necessary for suicidal intent, imminent self-harm, or inability to maintain safety. A patient can have an acute dangerous condition even when no established substance use disorder is present. Screening for longer-term substance risk belongs alongside, rather than ahead of, emergency assessment.

Prescription medications and combined exposure

Clinical review should identify opioids, sedative-hypnotics, stimulants, gabapentinoids when relevant, and other medications that may interact with alcohol or recreational drugs. Prescribed use, nonmedical use, physical dependence during appropriate care, diversion, and compulsive use are different clinical situations. Asking about combinations and intentions is more informative than interpreting any single risk score as a medication diagnosis.

Special Populations and Contexts

Pregnancy and postpartum care

Alcohol and drug screening during pregnancy must be performed with attention to fetal and maternal health, the patient's autonomy, confidentiality, legal context, and access to supportive care. The USPSTF recommends adult alcohol screening, including during pregnancy, and screening adults for unhealthy drug use when effective assessment and treatment are available. Evidence for the accuracy of individual questionnaires in pregnant patients is more limited than in general adult samples; prenatal screening should use a clinically appropriate, validated approach and be paired with nonpunitive follow-up. USPSTF alcohol recommendation; USPSTF drug recommendation.

Adolescents

Adolescents require developmentally appropriate questions and confidentiality safeguards. The USPSTF concluded that evidence was insufficient to determine the balance of benefits and harms of routine unhealthy alcohol or drug screening in primary care for adolescents aged 12 to 17; this is a statement about the evidence for a population-level recommendation, not proof that assessment is unnecessary when concerns exist. Pediatric settings often use adolescent-specific instruments such as CRAFFT, BSTAD, or S2BI rather than treating adult AUDIT-C or DAST-10 thresholds as automatically validated for teenagers. USPSTF alcohol guidance; USPSTF drug guidance.

Older adults and medically complex patients

Older patients may have alcohol-related risks at consumption levels that seem modest in younger adults because of medication interactions, frailty, changes in metabolism, falls risk, and chronic illness. Prescription sedative exposure can complicate screening questions. A score should be interpreted in relation to clinical vulnerability and treatment goals, especially where cognitive impairment, pain treatment, or multiple medications affect self-report accuracy.

Emergency departments and inpatient care

Acute care teams must address immediate stabilization before relying on elective screening. Questions asked during delirium, intoxication, extreme distress, or severe withdrawal may be unreliable. Once the patient is clinically able to participate, validated instruments can support discharge planning, secondary prevention, and connections to ongoing care. Documentation should distinguish the presentation that required emergency treatment from the subsequent assessment of long-term substance use risk.

Cultural adaptation, equity, and confidentiality

People may conceal substance use when a questionnaire feels punitive, when records may be shared without a clear explanation, or when care is associated with legal or social consequences. Confidential, voluntary and respectful administration can improve the integrity of the clinical exchange. Questionnaires should be offered in accessible language with trained interpretation when needed. A translated score sheet by itself is not proof that the instrument's statistical accuracy and thresholds have been established for that population.

Screening Programs, Digital Questionnaires, and Quality Assurance

Self-administered, clinician-administered, and digital formats

Questionnaires can be completed on paper, a tablet, or with a trained clinician. The USPSTF review found that self-administered and interviewer-administered approaches could have comparable accuracy in studied circumstances; this does not guarantee every digital modification is valid. A digital form must preserve the validated questions, answer options, look-back period, skip logic, and scoring. It should avoid diagnostic claims, provide privacy protections, and direct concerning results to an appropriate human clinical pathway. USPSTF full recommendation.

Why automated interpretation needs oversight

A screening score can be calculated electronically, but clinical judgment is still needed to interpret contradictions, cultural meaning, drug combinations, impairment, pregnancy, and acute safety. An AI chatbot or conversational companion that asks substance-use questions is not automatically a validated clinical screening instrument, a licensed assessor, or an evidence-based treatment service. Its accuracy, safety and effectiveness require independent study in the target population, and emergency escalation must remain reliable.

A meaningful implementation audit

Quality assurance should check how often eligible patients are offered a screen, whether questions and cutoffs are used correctly, whether results lead to timely follow-up, whether referrals are accessible, and whether patients experience the process as respectful. Recording more positive results is not sufficient evidence of improved health. Outcome evaluation should separately examine access, treatment engagement, reduced risky use, patient-reported functioning, and clinically relevant harms.

Frequently Asked Questions

Can AUDIT-C diagnose alcohol use disorder?

No. AUDIT-C identifies potentially unhealthy alcohol consumption patterns. A diagnosis requires a clinical assessment of recognized diagnostic features, functional consequences, relevant history, and the proper assessment period. Low scores also require context when abstinence or remission is present.

What does a DAST-10 score of three mean?

In a commonly used descriptive scheme, three is within the moderate range of reported drug-related problems. It justifies further clinical discussion and may warrant detailed assessment. It does not independently mean that the patient has a DSM-defined moderate substance use disorder, and it does not indicate the particular drug involved.

Why are ASSIST alcohol thresholds different from thresholds for other drugs?

WHO developed substance-specific scoring conventions and validation thresholds. The standard ASSIST alcohol score classifies 0–10 as low risk, whereas 0–3 is the low-risk range for most other substances. Each substance-specific score must be interpreted against its own scoring scheme, not against a universal total.

Do I need to complete all three questionnaires?

Usually, no. Instrument choice should follow the question being asked and the local workflow. A brief alcohol screen and an appropriate drug prescreen can be sufficient for routine first-line identification, while ASSIST may be more useful for a structured multi-substance assessment. Additional questions or instruments are appropriate when initial answers or clinical circumstances require deeper evaluation.

Does a negative result mean there is no overdose risk?

No. Overdose and toxic interactions can occur after limited exposure and do not require a high problem score or established disorder. Current symptoms, substance potency, co-use, route of administration, and recent exposure determine urgent risk more directly than a historical questionnaire.

How often should screening be repeated?

Frequency should follow the care setting, population, clinical risk, and local evidence-based workflow. Repeat assessment may be useful after a change in health, medication, exposure, pregnancy status, or treatment goals. A new score should be interpreted alongside the interval and circumstances rather than treated as a complete measure of recovery.

Can questionnaire scores measure remission or recovery?

A decline in self-reported risk may provide useful longitudinal information, but remission refers to changes in diagnostic features over time, and recovery includes functioning, health, stability, relationships, and personally meaningful goals. A screening tool cannot replace a multidimensional clinical and recovery assessment.

Clinical Synthesis

AUDIT-C, DAST-10, and ASSIST support different parts of the same evidence-informed clinical process. AUDIT-C measures unhealthy drinking patterns efficiently, DAST-10 characterizes reported drug-related problems, and WHO ASSIST builds a substance-specific risk profile across several classes. The most defensible use of any instrument combines standardized administration with a respectful discussion, attention to immediate safety, appropriate diagnostic assessment, and access to effective care. Screening results should clarify decisions while preserving the distinction between a risk signal, a clinical diagnosis, and a person's course of recovery.

Related Articles

The verified Substance Use Disorders and Addiction Recovery research chapter provides the broader clinical framework. Related published analyses include Anxiety and Substance Use, Substance-Induced Psychosis, Schizophrenia and Substance Use Disorders, Benzodiazepines for Anxiety, and OCD and Substance Use.

How Substance Use Disorders Are Diagnosed: DSM-5-TR and ICD-11 — the differences between DSM-5-TR and ICD-11 diagnostic frameworks and severity concepts.

Addiction Severity and Level of Care: How Treatment Needs Are Assessed — severity, multidimensional treatment needs, and clinical care-setting selection.

What Is a Dual Diagnosis? Substance Use and Co-Occurring Mental Disorders — general integrated assessment and care for co-occurring mental illness and addiction.

References

Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics. (2021). Peer-reviewed research article. Full text.

National Institute on Drug Abuse. Drug Abuse Screening Test (DAST-10). NIH Common Data Elements Repository. Instrument record.

O'Connor, E. A., Perdue, L. A., Senger, C. A., et al. (2018). Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320, 1910–1928. doi:10.1001/jama.2018.12086.

Patnode, C. D., Perdue, L. A., Rushkin, M., et al. (2020). Screening for unhealthy drug use: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 323, 2310–2328. doi:10.1001/jama.2019.21381.

Skinner, H. A. (1982). The Drug Abuse Screening Test. Addictive Behaviors, 7, 363–371. doi:10.1016/0306-4603(82)90005-3.

U.S. Preventive Services Task Force. (2018). Unhealthy alcohol use in adolescents and adults: Screening and behavioral counseling interventions. Final recommendation.

U.S. Preventive Services Task Force. (2020). Unhealthy drug use: Screening. Final recommendation.

Validation of the Drug Abuse Screening Test (DAST-10): A study on illicit drug use among Chinese pregnant women. (2015). Peer-reviewed full text.

World Health Organization. (2010). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Manual for use in primary care. Official WHO publication.

World Health Organization. (2012). The ASSIST-linked brief intervention for hazardous and harmful substance use: Manual for use in primary care. Official WHO publication.